TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31012999

Group type: EXPERIMENTAL
Intervention: Herbal extract
Number of subjects: 77

Group type: COMPARATOR
Intervention: 2.5% benzoyl peroxide
Number of subjects: 77
Study: 29098254

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26122744

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 24461572

Group type: EXPERIMENTAL
Intervention: Oral stimulation program for 15 min at least for 10 days before introduction of oral feeding
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no oral stimulation)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Oral stimulation program
Number of subjects: 86
Study: 22341836

Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20336162

Group type: EXPERIMENTAL
Intervention: Octreotide LAR (long-acting release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17693960

Group type: COMPARATOR
Intervention: Diet C: day/night formulas administered in synchrony with the environment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet B: 06:00-18:00 normal initiation milk, 18:00-06:00 dissociated night formula
Number of subjects: 30
Study: 16296426

Group type: EXPERIMENTAL
Intervention: Ozone treatment (HealOzone) applied once for 40 seconds to the test molar.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Untreated control lesions (contra‐lateral lesions).
Number of subjects: 41
Study: 11235682

Group type: EXPERIMENTAL
Intervention: Full investigation group (mediastinoscopy and computed tomography of the chest)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Full investigation group
Number of subjects: 634

Group type: COMPARATOR
Intervention: Limited investigation group (bone scintigraphy and computed tomographic scanning of the head, liver, and adrenal glands)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Limited investigation group
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Full investigation strategy
Number of subjects: 634
Study: 9512198

Group type: EXPERIMENTAL
Intervention: High fat diet (48% energy as fat)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low fat diet (22.2% energy as fat)
Number of subjects: 39
Study: 7999657

Group type: EXPERIMENTAL
Intervention: Patient-assisted epidural analgesia (fentanyl 10 mcg/mL and bupivacaine 1 mg/mL for the first 2 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patient-assisted epidural analgesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Continuous epidural infusion
Number of subjects: 62
Study: 3180725

Group type: EXPERIMENTAL
Intervention: Eight-week communications training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help meetings (Control)
Number of subjects: 0
Study: 30299520

Group type: EXPERIMENTAL
Intervention: Internal condition
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: External condition
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 140
Study: 31299670

Group type: EXPERIMENTAL
Intervention: Likelihood-based multiple imputation strategy for imputing observations below the limit of detection (LOD) while accounting for differential batch assignment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete-case analysis including batch indicator terms in the analysis model.
Number of subjects: 0
Study: 27876528

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) preserved multipurpose care solution (MPS)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Peroxide-based solution system
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Solution-induced corneal staining (SICS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Participants with substantial bioburden on lenses or storage case
Number of subjects: 139
Study: 25878904

Group type: EXPERIMENTAL
Intervention: Active tDCS (transcranial direct current stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 60
Study: 23588130

Group type: EXPERIMENTAL
Intervention: Tailored message addressing perceived barriers to HPV vaccination
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nontailored message about HPV vaccination
Number of subjects: 94
Study: 20652715

Group type: EXPERIMENTAL
Intervention: Transfascial nonabsorbable sutures
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metal tacks
Number of subjects: 40
Study: 18847523

Group type: EXPERIMENTAL
Intervention: Phenylephrine-lignocaine mixture (Cophenylcaine)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Xylometazoline (Otrivine)
Number of subjects: 73
Study: 17342510

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fusion cage
Number of subjects: 24
Study: 15037937

Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent nitroglycerin ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin-free placebo
Number of subjects: 60
Study: 11102592

Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring (IVR-2)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control (non-use of ring)
Number of subjects: 166
Study: 8741469

Group type: EXPERIMENTAL
Intervention: Continuous epidural block instituted prior to induction of anesthesia and maintained throughout surgery (Group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous epidural block instituted upon peritoneal closure and maintained thereafter (Group 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 16
Study: 1397911

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Air
Number of subjects: 56
Study: 3894474

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg
Number of subjects: 12
Study: 30511879

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg twice daily)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 28347608

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine delivered as sprays (MAD group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine delivered as drops (syringe group)
Number of subjects: 106
Study: 26279172

Group type: EXPERIMENTAL
Intervention: Home-based virtual reality balance training (n=11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional home balance training (n=12)
Number of subjects: 23
Study: 24823456

Group type: EXPERIMENTAL
Intervention: 2 nights of 4 hours in bed
Number of subjects: 13

Group type: COMPARATOR
Intervention: 2 nights of 10 hours in bed
Number of subjects: 13
Study: 22995383

Group type: COMPARATOR
Intervention: Controls (alive patients without VT/VF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients in the arrhythmia group (with VT/VF/death outcomes)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with VT/VF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Decrease in QTVI after PVC
Number of subjects: 33
Study: 19493173

Group type: EXPERIMENTAL
Intervention: Self-guided group with process goals
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-guided group with outcome goals
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Groups with process goals
Number of subjects: 48

Group type: COMPARATOR
Intervention: Outcome goal participants
Number of subjects: 48
Study: 17323429

Group type: EXPERIMENTAL
Intervention: Topography-guided customized aspheric treatment zone (CATz) ablation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison between CATz and conventional ablation
Number of subjects: 54
Study: 15310345

Group type: EXPERIMENTAL
Intervention: Combination of inhaled medical air and titrated intravenous midazolam
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Combination of inhaled mixture of sevoflurane 0.3% and nitrous oxide 40% in oxygen with titrated intravenous midazolam
Number of subjects: 697
Study: 12796591

Group type: EXPERIMENTAL
Intervention: Daily schedule of topotecan (1.5 mg/m2 daily for 5 days every 3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous-infusion schedule of topotecan (1.3 mg/m2 per day over 72 hours every 4 weeks)
Number of subjects: 60
Study: 10479878

Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally before and after RS (n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally after RS (n = 25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no therapy after RS) (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally (both before and after RS)
Number of subjects: 100
Study: 8753634

Group type: EXPERIMENTAL
Intervention: Early Discharge (ED) group (n = 319)
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: Concurrent group (n = 456)
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Preprogram control group (n = 542)
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: All groups (ED, concurrent, preprogram control)
Number of subjects: 1317
Study: 1888047

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.1 mEq sodium bicarbonate added to each 20 ml (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:300,000 epinephrine (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control period prior to epidural catheter insertion
Number of subjects: 60
Study: 7158401

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ioxaglate
Number of subjects: 40

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 40
Study: 4003494

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30552264

Group type: EXPERIMENTAL
Intervention: Humanoid robot distraction during IVI
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care during IVI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Humanoid robot distraction
Number of subjects: 80
Study: 26037728

Group type: EXPERIMENTAL
Intervention: Lactoferrin 250 mg capsules once daily for eight consecutive weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ferrous sulphate 150 mg capsules once daily for eight consecutive weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 200
Study: 25078310

Group type: EXPERIMENTAL
Intervention: Alemtuzumab-based treatment (alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Basiliximab-based treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Alemtuzumab-based treatment
Number of subjects: 852

Group type: COMPARATOR
Intervention: Basiliximab-based treatment
Number of subjects: 852
Study: 22177854

Group type: EXPERIMENTAL
Intervention: Pedometer-based program with socio-cognitive intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study: 19933534

Group type: EXPERIMENTAL
Intervention: Hemofiltration during CPB
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Perioperative steroid therapy
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 185
Study: 18338980

Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic training (both high and moderate intensity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strength training and moderate-intensity aerobic training
Number of subjects: 40
Study: 16187727

Group type: EXPERIMENTAL
Intervention: Coralline hydroxyapatite (CH) backfill
Number of subjects: 12

Group type: COMPARATOR
Intervention: No backfill
Number of subjects: 12
Study: 12581014

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 30
Study: 8863008

Group type: EXPERIMENTAL
Intervention: Nibbling diet (12 meals per day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gorging diet (3 meals per day)
Number of subjects: 11
Study: 1521954

Group type: EXPERIMENTAL
Intervention: Training at lactate threshold (at LT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training above lactate threshold (greater than LT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 25
Study: 6386485

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Colestipol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Probucol plus Colestipol
Number of subjects: 42
Study: 30506623

Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 formulations, each for two 1-week periods)
Number of subjects: 0
Study: 29506183

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Protein-rich diet
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat-rich diet
Number of subjects: 158
Study: 26892001

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) coupled with Virtual Reality Exposure Therapy (VRET)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) alone
Number of subjects: 120
Study: 25315148

Group type: EXPERIMENTAL
Intervention: Postal questionnaires assessing physical activity (Godin score)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Postal questionnaires assessing diet (DINE Fibre score)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Postal questionnaires assessing diet (DINE Total Fat score)
Number of subjects: 903
Study: 22395336

Group type: EXPERIMENTAL
Intervention: WATCHMAN Left Atrial Appendage Closure Device
Number of subjects: 6000000

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6000000

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6000000

Group type: COMPARATOR
Intervention: Dabigatran (150 mg twice a day)
Number of subjects: 6000000

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 6000000
Study: 20665351

Group type: EXPERIMENTAL
Intervention: Trendelenburg chest optimization (TCO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SBT following TCO
Number of subjects: 12
Study: 17386112

Group type: EXPERIMENTAL
Intervention: Rest transthoracic echocardiography (TTE) and Dobutamine stress echocardiography (DSE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 20
Study: 15592928

Group type: EXPERIMENTAL
Intervention: (S)-[11C]CGP12388 PET
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 6
Study: 11880018

Group type: EXPERIMENTAL
Intervention: BiPAP 14/8 cm H(2)O with RR at 10 breaths/min
Number of subjects: 213

Group type: COMPARATOR
Intervention: CPAP 8 cm H(2)O
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: BiPAP 14/8 cm H(2)O
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Rapid induction with 2.0 mg/kg propofol followed by P5
Number of subjects: 213
Study: 9795848

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and implantation of a silicone IOL with posterior continuous curvilinear capsulorhexis (PCCC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phacoemulsification and implantation of a silicone IOL without PCCC (control group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no PCCC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PCCC group
Number of subjects: 50
Study: 7652118

Group type: EXPERIMENTAL
Intervention: New method of estimating baroreflex control from spontaneous changes in systolic pressure and pulse interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method of assessing baroreflex control through pharmacological manipulations of blood pressure
Number of subjects: 0
Study: 2509250

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo IM injection every 4 weeks for 12 weeks (group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A) in patients with large uteri
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo IM injection every 4 weeks for 12 weeks (group B) in patients with large uteri
Number of subjects: 18
Study: 326403

Group type: EXPERIMENTAL
Intervention: Ftorafur combined with mitomycin C
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ftorafur combined with methyl-CCNU
Number of subjects: 25
Study: 31617096

Group type: EXPERIMENTAL
Intervention: Low-pressure carbon dioxide pneumoperitoneum (8 mm Hg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: High-pressure carbon dioxide pneumoperitoneum (14 mm Hg)
Number of subjects: 101
Study: 31883249

Group type: EXPERIMENTAL
Intervention: Fissurit FX sealant
Number of subjects: 55

Group type: COMPARATOR
Intervention: Grandioseal nanofilled fissure sealant
Number of subjects: 55
Study: 28720281

Group type: EXPERIMENTAL
Intervention: H9N2 vaccine with AS03 adjuvant (1.9µgHA+AS03A, 1.9µgHA+AS03B, 3.75µgHA+AS03A, 3.75µgHA+AS03B)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: H9N2 vaccine without adjuvant (15µg HA)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: H9N2 vaccine (any formulation) administered a third dose on day 182
Number of subjects: 420

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 420
Study: 25673443

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF) 20 mg, 3 times a day for 8 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Acitretin 30 mg, once a day for 8 weeks
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Acitretin
Number of subjects: 115
Study: 24968737

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU) every 14 days for 4 months
Number of subjects: 53
Study: 21849541

Group type: EXPERIMENTAL
Intervention: One week of training on complex visuomotor rotation
Number of subjects: 0
Study: 19501984

Group type: EXPERIMENTAL
Intervention: Follicular phase (F)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Luteal phase (L)
Number of subjects: 138
Study: 17714105

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 15
Study: 15171574

Group type: EXPERIMENTAL
Intervention: Rigid above-knee plaster dressing applied at operation (n = 78)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-rigid dressing regime (control group, n = 76)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Rigid dressing
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Post-trial questionnaire responses
Number of subjects: 154
Study: 11570650

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (doing nothing)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and Chewing gum
Number of subjects: 45
Study: 9135191

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 97
Study: 7911132

Group type: EXPERIMENTAL
Intervention: alprazolam+exposure (AE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo+exposure (PE)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: alprazolam+relaxation (AR)
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo+relaxation (PR)
Number of subjects: 144
Study: 3318436

Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 mg taken at bedtime)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 489

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 489
Study: 31900091

Group type: EXPERIMENTAL
Intervention: Isotonic exercises and relaxing techniques, performed twice a week for one month.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Self-care guidelines (Control group).
Number of subjects: 19
Study: 30550400

Group type: EXPERIMENTAL
Intervention: Self-selected motivational music
Number of subjects: 17

Group type: COMPARATOR
Intervention: No music
Number of subjects: 17
Study: 28974425

Group type: EXPERIMENTAL
Intervention: Latent heat device (n=25)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Liposomal spray (n=28)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Heated warm compress (n=28)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no MG dropout)
Number of subjects: 81
Study: 26970217

Group type: EXPERIMENTAL
Intervention: Nurse‐delivered sleep‐promoting interventions augmented by sleep hygiene education and environmental control to minimize sleep disruption
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nurse‐delivered sleep‐promoting interventions
Number of subjects: 112
Study: 24736285

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 21242856

Group type: EXPERIMENTAL
Intervention: Head elevation increased or decreased between 0 and 40 degrees from baseline level (30 degrees) in increments or decrements of 10 degrees
Number of subjects: 10